Tabrecta and Stroke - a phase IV clinical study of FDA data

Summary:

Stroke is reported as a side effect among people who take Tabrecta (capmatinib hydrochloride), especially for people who are male, 60+ old, also take Mirtazapine, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Stroke when taking Tabrecta. It is created by eHealthMe based on reports of 2,093 people who have side effects when taking Tabrecta from the FDA, and is updated regularly.

What is Tabrecta?

Tabrecta has active ingredients of capmatinib hydrochloride. eHealthMe is studying from 2,095 Tabrecta users. Check the latest studies of Tabrecta.

What is Stroke?

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen) is found to be associated with 2,323 drugs and 3,028 conditions by eHealthMe. Check the latest studies of Stroke.

On Apr, 15, 2026

2,093 people reported to have side effects when taking Tabrecta.
Among them, 10 people (0.48%) have Stroke.

Among these 10 people:

What is the gender of people who have Stroke when taking Tabrecta? *

female: 30 %
male: 70 %

What is the age of people who have Stroke when taking Tabrecta? *

What are other drugs people take besides Tabrecta? *

What are other side effects people have besides Stroke? *

Weakness: 1 person, 10.00%
Swallowing Difficulty: 1 person, 10.00%
Speech Impairment (Adult) (inability to speak (adult)): 1 person, 10.00%
Speech Disorder: 1 person, 10.00%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 10.00%
Pulmonary Thrombosis (scarring in the lungs): 1 person, 10.00%
Peripheral Swelling: 1 person, 10.00%
Joint Swelling: 1 person, 10.00%
Headache (pain in head): 1 person, 10.00%
Fatigue (feeling of tiredness): 1 person, 10.00%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 4 people, 40.00%
Squamous Cell Carcinoma Of Skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin): 1 person, 10.00%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 1 person, 10.00%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tabrecta and have Stroke?

- Check whether Stroke is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tabrecta:

Tabrecta (2,095 reports)

Stroke treatments and more:

Stroke (334,635 reports)

Browse all side effects of Tabrecta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Stroke:

Stroke (2,323 drugs)

Browse all the conditions that are associated with Stroke:

Stroke (3,028 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on capmatinib hydrochloride (the active ingredients of Tabrecta) and Tabrecta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.